BMY - Bristol-Myers Squibb Company
| Previous Close | 50.92 |
| Open | 51.36 |
| Bid | 51.65 x 2900 |
| Ask | 53.00 x 900 |
| Day's Range | 51.06 - 52.05 |
| 52 Week Range | 46.94 - 70.05 |
| Volume | 8,410,170 |
| Avg. Volume | 8,747,556 |
| Market Cap | 84.156B |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | 59.06 |
| EPS (TTM) | 0.87 |
| Earnings Date | Jan 24, 2019 |
| Forward Dividend & Yield | 1.64 (3.15%) |
| Ex-Dividend Date | 2019-01-03 |
| 1y Target Est | 59.75 |
Reuters•3 hours agoBristol-Myers gets $1.6 billion offer for French consumer health unit
Bristol-Myers said it estimates the potential deal would be approximately $0.04 dilutive to 2019 earnings. The offer by Taisho, which has its presence in anti-inflammatory analgesic, cold and flu and hair growth segments in Japan and Southeast Asia, is structured in the form of a "put option" agreement, the companies said. Upon exercise of the put option, Taisho would acquire UPSA as well as Bristol-Myers Squibb's assets and liabilities relating to the UPSA product portfolio, the companies said.
- Reuters•3 hours ago
Bristol-Myers gets $1.6 billion offer for French consumer health unit
Bristol-Myers said it estimates the potential deal would be approximately $0.04 dilutive to 2019 earnings. The offer by Taisho, which has its presence in anti-inflammatory analgesic, cold and flu and hair growth segments in Japan and Southeast Asia, is structured in the form of a "put option" agreement, the companies said. Upon exercise of the put option, Taisho would acquire UPSA as well as Bristol-Myers Squibb's assets and liabilities relating to the UPSA product portfolio, the companies said.
- The Wall Street Journal•3 hours ago
[$$] Bristol-Myers to Sell French Unit to Japan's Taisho for $1.6B
Bristol-Myers Squibb’s French UPSA unit develops and makes drugs and supplements, including pain and cough medicine, as well as vitamin supplements and sleep medication. Taisho’s offer for UPSA comes in the form of a ‘put option’ agreement and is subject to Bristol-Myers Squibb’s exercise of the option, the U.S. company said. Upon exercise of the put option, the two companies would execute a stock and assets purchase deal in which Taisho would buy all issued and outstanding shares of UPSA, as well as Bristol-Myers Squibb’s assets and liabilities relating to UPSA’s product portfolio, the company said.
- Business Wire•4 hours ago
Bristol-Myers Squibb Announces Offer from Taisho Pharmaceutical Holdings Co., Ltd to Purchase UPSA
Bristol-Myers Squibb Company (BMY) today announced that Taisho Pharmaceutical Holdings Co., Ltd. (Taisho) has offered to purchase Bristol-Myers Squibb’s UPSA consumer health business for $1.6 billion. UPSA develops and delivers important consumer medicines for patients in France, across Europe and additional countries.
- Zacks•12 hours ago
Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod
Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.
Market Realist•18 hours agoAnalyzing Pfizer’s Revenues in December
Pfizer’s net revenues were $39.7 billion in the first nine months of 2018—compared to $38.8 billion during the same period in 2017. Pfizer’s revenues grew ~2% YoY (year-over-year). Pfizer expects that its net revenues for fiscal 2018 will be $53.0 billion–$53.7 billion. Pfizer updated its revenue guidance after the third quarter. Previously, Pfizer expected revenues of $53.0 billion–$55.0 billion for fiscal 2018. Wall Street analysts expect Pfizer to report net revenues of $53.6 billion in fiscal 2018.
- Zacks•21 hours ago
Merck's Keytruda Gets EU Nod as Adjuvant Therapy for Melanoma
Merck (MRK) gains an EU approval for Keytruda as an adjuvant therapy pertaining to adult patients with advanced melanoma.
- Zacks•22 hours ago
BMY vs. AZN: Which Stock Should Value Investors Buy Now?
BMY vs. AZN: Which Stock Is the Better Value Option?
- Zacks•2 days ago
Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod
Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).
- Business Wire•2 days ago
Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance
Bristol-Myers Squibb Company (BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients treated with standard-of-care checkpoint inhibitors. “Our newly opened R&D site in Kendall Square is focused on better understanding, and ultimately overcoming, the challenge of I-O resistance. Through the study, researchers will explore the role of tissue and circulating biomarkers on treatment sensitivity and resistance.
- Zacks•2 days ago
Merck to Acquire Europe's Antelliq Group for $2.4 Billion
Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.
- Zacks•2 days ago
Lilly (LLY) to Acquire Pain Candidate From Private Biotech
Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.
Zacks•2 days agoThe Zacks Analyst Blog Highlights: Comcast, American Express, Bristol-Myers, T-Mobile and General Motors
The Zacks Analyst Blog Highlights: Comcast, American Express, Bristol-Myers, T-Mobile and General Motors
- Business Wire•2 days ago
Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform
The new collaboration will explore modulating RNA splicing to develop potential first-in-class therapies that would direct the immune system to target cancer cells and help more patients experience the benefits of immunotherapy.
- Business Wire•2 days ago
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the expanded approval of Sprycel , in combination with chemotherapy, to include the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia .
- Reuters•2 days ago
Taisho said to near $1.6 billion deal for Bristol-Myers's UPSA - Bloomberg
Bristol-Myers Squibb declined to comment on the report, but said it was still considering options for the strategic review of UPSA that was announced in June. Earlier this month, Takeda Pharmaceutical won shareholder approval for its $59 billion takeover of London-listed Shire (SHP.L), allowing the company to join the ranks of the world's top 10 drugmakers. German drugmaker Stada (STAGn.D) and Italian healthcare company Angelini were among the final bidders for Bristol-Myers' UPSA unit, according to a Reuters report in November.
- Reuters•2 days ago
Taisho said to near $1.6 bln deal for Bristol-Myers's UPSA- Bloomberg
Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd is said to be close to a $1.6 billion deal for Bristol-Myers Squibb Co's French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter. Bristol-Myers Squibb declined to comment on the report, but said it was still considering options for the strategic review of UPSA that was announced in June. The report comes amid a flurry of deals among drugmakers, who are trying to survive a contraction in the domestic drug market due to government-led price cuts and promotion of generic drugs.
- Bloomberg•2 days ago
Taisho Nears $1.6 Billion Deal for Bristol-Myers Unit
A deal could value the OTC operations, known as UPSA, at about $1.6 billion, said the people. U.S. pharma giant Bristol-Myers has sought to sell the unit amid a push to streamline its business globally to focus on other growth areas, the people said. Any deal would add to the $428.7 billion of announced acquisitions of health-care companies this year, 27 percent more than the same period in 2017, according to data compiled by Bloomberg.
- CNBC•5 days ago
Your first trade for Friday, December 14
The " Fast Money " traders shared their first moves for the market open. Steve Grasso was a buyer of the Utilities ETF XLU . Karen Finerman was a buyer of JPMorgan JPM . Dan Nathan was a seller of Costco COST .
- Zacks•5 days ago
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Zacks•5 days agoZacks.com featured highlights include: Nexstar Media, Bristol-Myers Squibb, Capital One Financial, Helmerich & Payne and Progressive
Zacks.com featured highlights include: Nexstar Media, Bristol-Myers Squibb, Capital One Financial, Helmerich & Payne and Progressive
- ACCESSWIRE•5 days ago
Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Novartis
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...
Zacks•6 days agoBristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Bristol-Myers Squibb (BMY) closed at $53.64 in the latest trading session, marking a +0.37% move from the prior day.
- Zacks•6 days ago
J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study
J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.
- Zacks•6 days ago
Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA
Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.
